MapLight Therapeutics, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
MPLT Nasdaq 2836 www.maplightrx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for MapLight Therapeutics, Inc.

MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - Jan 9th, 2026 5:00 am
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis - Jan 5th, 2026 5:00 am
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies - Dec 16th, 2025 5:00 am
MapLight Therapeutics Reports Third Quarter Financial Results and Highlights Corporate Progress - Dec 4th, 2025 5:00 am
MapLight Therapeutics, Gold Royalty, and More Stocks See Action From Activist Investors - Nov 7th, 2025 5:26 pm
MapLight Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares - Oct 29th, 2025 7:06 am
Sector Update: Health Care Stocks Increase Late Afternoon - Oct 27th, 2025 1:57 pm
MapLight Therapeutics Announces Pricing of Initial Public Offering - Oct 26th, 2025 3:30 pm